VBI Vaccines Inc. [NASDAQ: VBIV] price surged by 13.68 percent to reach at $0.52. The company report on June 22, 2020 that VBI Vaccines Announces Data from VBI-1901 Presented at AACR 2020: Partial Response Observed, Promising Biomarker Strategy Identified.
– Confirmed durable partial response with recurrent GBM tumor reduction of more than 50%.
– Normal baseline CD4+/CD8+ T cell ratio identified as potentially predictive biomarker associated with tumor responses.
A sum of 20639518 shares traded at recent session while its average daily volume was at 14.19M shares. VBI Vaccines Inc. shares reached a high of $4.68 and dropped to a low of $3.78 until finishing in the latest session at $4.32.
The one-year VBIV stock forecast points to a potential upside of 47.64. The average equity rating for VBIV stock is currently 1.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on VBI Vaccines Inc. [VBIV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VBIV shares is $8.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VBIV stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for VBI Vaccines Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 16, 2019. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price to Buy. The new note on the price target was released on November 01, 2017, representing the official price target for VBI Vaccines Inc. stock. Previously, the target price had yet another raise to $6, while Laidlaw analysts kept a Buy rating on VBIV stock.
The Average True Range (ATR) for VBI Vaccines Inc. is set at 0.67, with the Price to Sales ratio for VBIV stock in the period of the last 12 months amounting to 437.79. The Price to Book ratio for the last quarter was 10.36.
VBIV Stock Performance Analysis:
VBI Vaccines Inc. [VBIV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.73. With this latest performance, VBIV shares gained by 39.35% in over the last four-week period, additionally plugging by 210.79% over the last 6 months – not to mention a rise of 490.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VBIV stock in for the last two-week period is set at 51.72, with the RSI for the last a single of trading hit 47.22, and the three-weeks RSI is set at 54.41 for VBI Vaccines Inc. [VBIV]. The present Moving Average for the last 50 days of trading for this stock 3.27, while it was recorded at 4.44 for the last single week of trading, and 1.65 for the last 200 days.
Insight into VBI Vaccines Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and VBI Vaccines Inc. [VBIV] shares currently have an operating margin of -2075.96 and a Gross Margin at -310.09. VBI Vaccines Inc.’s Net Margin is presently recorded at -2467.94.
Return on Total Capital for VBIV is now -42.55, given the latest momentum, and Return on Invested Capital for the company is -54.78. Return on Equity for this stock declined to -58.82, with Return on Assets sitting at -42.20. When it comes to the capital structure of this company, VBI Vaccines Inc. [VBIV] has a Total Debt to Total Equity ratio set at 18.47. Additionally, VBIV Total Debt to Total Capital is recorded at 15.59, with Total Debt to Total Assets ending up at 13.34. Long-Term Debt to Equity for the company is recorded at 0.93, with the Long-Term Debt to Total Capital now at 0.78.
Reflecting on the efficiency of the workforce at the company, VBI Vaccines Inc. [VBIV] managed to generate an average of -$438,504 per employee. Receivables Turnover for the company is 17.28 with a Total Asset Turnover recorded at a value of 0.02.
VBIV Stock EPS
With the latest financial reports released by the company, VBI Vaccines Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VBIV.
VBI Vaccines Inc. [VBIV] Insider Position Details
There are presently around $340 million, or 44.45% of VBIV stock, in the hands of institutional investors. The top three institutional holders of VBIV stocks are: PERCEPTIVE ADVISORS LLC with ownership of 45,951,556, which is approximately 0% of the company’s market cap and around 5.26% of the total institutional ownership; BLACKROCK INC., holding 11,678,848 shares of the stock with an approximate value of $50.45 million in VBIV stocks shares; and VANGUARD GROUP INC, currently with $13.78 million in VBIV stock with ownership of nearly 7.372% of the company’s market capitalization.
Positions in VBI Vaccines Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 46 institutional holders increased their position in VBI Vaccines Inc. [NASDAQ:VBIV] by around 5,263,005 shares. Additionally, 31 investors decreased positions by around 2,484,866 shares, while 11 investors held positions by with 70,935,241 shares. The mentioned changes placed institutional holdings at 78,683,112 shares, according to the latest SEC report filing. VBIV stock had 16 new institutional investments in for a total of 994,940 shares, while 13 institutional investors sold positions of 1,526,083 shares during the same period.